Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00249873
Status:
COMPLETED
Last Update Posted:
2015-06-15
First Post:
2005-11-04
Brief Title:
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events ACTIVE A
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin With Factorial Evaluation of Irbesartan for the Prevention of Vascular Events in Patients With Atrial Fibrillation
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if the combination of clopidogrel 75mg once daily od plus aspirin 100mg daily recommended dose is better than aspirin alone 100mg daily recommended dose for preventing vascular events such as stroke and heart attack during approximately three years of follow-up in patients with atrial fibrillation associated with at least one major risk factor of vascular event such as elderly blood pressure increase history of stroke or transient ischemic attack or left ventricular dysfunction etc The study will also accept patients with atrial fibrillation and unwilling to take oral anticoagulant therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None